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Abstract
Bluetongue (BT) is an arthropod-borne viral disease, which primarily affects ruminants in tropical and temperate regions of
the world. Twenty six bluetongue virus (BTV) serotypes have been recognised worldwide, including nine from Europe and
fifteen in the United States. Identification of BTV serotype is important for vaccination programmes and for BTV
epidemiology studies. Traditional typing methods (virus isolation and serum or virus neutralisation tests (SNT or VNT)) are
slow (taking weeks, depend on availability of reference virus-strains or antisera) and can be inconclusive. Nucleotide
sequence analyses and phylogenetic comparisons of genome segment 2 (Seg-2) encoding BTV outer-capsid protein VP2
(the primary determinant of virus serotype) were completed for reference strains of BTV-1 to 26, as well as multiple
additional isolates from different geographic and temporal origins. The resulting Seg-2 database has been used to develop
rapid (within 24 h) and reliable RT–PCR-based typing assays for each BTV type. Multiple primer-pairs (at least three designed
for each serotype) were widely tested, providing an initial identification of serotype by amplification of a cDNA product of
the expected size. Serotype was confirmed by sequencing of the cDNA amplicons and phylogenetic comparisons to
previously characterised reference strains. The results from RT-PCR and sequencing were in perfect agreement with VNT for
reference strains of all 26 BTV serotypes, as well as the field isolates tested. The serotype-specific primers showed no cross-
amplification with reference strains of the remaining 25 serotypes, or multiple other isolates of the more closely related
heterologous BTV types. The primers and RT–PCR assays developed in this study provide a rapid, sensitive and reliable
method for the identification and differentiation of the twenty-six BTV serotypes, and will be updated periodically to
maintain their relevance to current BTV distribution and epidemiology (http://www.reoviridae.org/dsRNA_virus_proteins/
ReoID/rt-pcr-primers.htm).
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Introduction
Bluetongue (BT) is an arthropod-transmitted hemorrhagic
disease of wild and domestic ruminants. It is enzootic in many
tropical, subtropical and some temperate regions, including much
of the Americas, Africa, southern Asia and northern Australia,
coincident with the geographic distribution and seasonal activity of
competent Culicoides vector insects [1,2,3]. BT can have major
effects on animal health, particularly in naı ¨ve ruminant popula-
tions, restricting international trade in livestock. It is therefore
listed as a ‘notifiable’ disease by the Office International des
Epizooties (OIE) [4,5,6].
The bluetongue virus (BTV) genome is composed of ten
linear segments of double-stranded RNA (dsRNA), which
encode eleven distinct virus proteins. Seven of these (VP1 to
VP7) are structural components of the icosahedral virus capsid,
while four (NS1 to NS4) are non-structural proteins that have
been identified in BTV-infected cells [7,8,9,10]. The BTV
outer-capsid proteins VP2 and VP5, which are encoded by
g e n o m es e g m e n t s2a n d6( S e g - 2a nd Seg-6) respectively, are
primarily involved in cell-attachment and entry during the early
stages of infection. They also contain epitopes (particularly VP2)
that bind neutralising antibodies generated during infection of
the mammalian host [11,12,13,14]. The specificity of these
reactions in serum neutralisation or virus neutralisation tests
(SNT or VNT), shows a close correlation with variations in the
amino acid (aa) sequence of VP2, and has been used to identify
26 distinct serotypes (including the recent identification of BTV-
25 from Switzerland and BTV-26 from Kuwait) [15,16,17,
18,19,20].
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e32601Phylogenetic analyses of Seg-2 show that it represents the least
conserved region of the BTV genome, separating primarily into 26
distinct clades that accurately reflect virus types identified in VNT
or SNT (with ,32% nucleotype (nt) sequence variation within
type: 28.5–59.5% variation between types) [17,21]. Full genome
sequence analyses of multiple BTV isolates from different
geographic regions has identified distinct ‘regional groups’
(topotypes): including the major ‘eastern’ and ‘western’ lineages
(topotypes) identified by Maan et al [18,21,22]. To a lesser extent
regional variations are also evident within individual serotypes,
with ,21.8% nt variation in Seg-2 between strains belonging to
the same topotype and serotype. The ‘eastern’ group includes
BTV isolates from South East Asia, India, China or Australia,
while the ‘western’ group includes viruses primarily from Africa
and North or South America [16,23,24]. There is also evidence for
further distinct topotypes represented by certain viruses from
China and Australia, as well as the recently discovered BTV types
25 and 26 [18,19,22].
Nucleotide sequence based typing methods (including phyloge-
netic comparisons of Seg-2 and real-time or conventional RT-
PCR assays) are becoming increasingly important for the diagnosis
and identification of individual BTV serotypes [18,21,22]. Due to
the significant level of sequence variation that can exist in Seg-2
between BTV isolates from different geographic origins but
belonging to the same serotype (up to 32% nt variation), it is
becoming increasingly important to identify reference strains for
the major topotypes that exist within each serotype. Where
appropriate we have therefore added the letters ‘e’ or ‘w’ to the
designations for reference or field strain of different BTV
serotypes, to indicate that they belong to either the major eastern
or western topotype. Recent isolates of BTV-25 and 26 represent
additional distinct western and eastern topotypes, that we can
identify as ‘w2’and ‘e2’ respectively [21,22].
Prior to 1998, BTV had caused only periodic and relatively
short-lived epizootics in southern Europe, involving a single
serotype on each occasion [25,26]. However, exotic BTV strains
have arrived in Europe almost every year from 1998 to 2011,
including a total nine distinct serotypes and viruses belonging to
both eastern (e) and western (w) topotypes (BTV-1e, -1w, -2w, -4w,
-6w, -8w, -9e, -11w, -16e and 25w2) [27,28,29,30,31]. Conse-
quently outbreaks (most notably those caused by a strain of BTV-
8w) spread to almost the whole of Europe, including several North
European countries where BTV had not previously been reported
(reviewed by [21,24,26,32]).
BTV has recently also expanded its geographic range in other
parts of the world. Multiple additional BTV types were identified in
Israel, including: BTV-5w, -8w, -15w (in 2006); BTV-24w (in 2008);
BTV-2(in2010)andBTV-12in2011(thefirsttimethesetypeshave
beendetected inthe Mediterranean region)[33].BTV-1w, -4w,-8w
and -16w were detected in Oman during 2009 [34] and BTV-26
was identified in Kuwait during 2010 [18]. The geographic
proximity of these outbreaks to Europe suggests that the BTV
strains involved could represent future threats to the region. Since
1999 multiple, previously exotic BTV strains (BTV-1w, -3w, -5w, -
6w, -14w, -19w, -22w and -24w) were also detected in the south-
eastern United States, most likely as a result of northward spread
from the Caribbean Basin [35,36]. More recently in 2008, two
further strains of BTV-9, -12, were identified in Florida and Texas
respectively [36]. BTV-7w and -2e were also detected in northern
Australia during 2007 and 2008 respectively [37,38].
The inactivated or live-attenuated BTV vaccines that are
currently available are serotype-specific [39]. Rapid and reliable
identification of virus serotype can therefore play an important
part in the design and implementation of appropriate control
measures. Identification of BTV ‘type’ also demonstrates conclu-
sively that the virus belongs to the BTV species, confirming any
initial diagnoses by other means [40], and can help to map the
origins, movement and spread of individual virus strains.
Serum neutralisation tests can also show a broad heterotypic
response to multiple BTV serotypes, particularly if the animal
tested has previously been infected or vaccinated sequentially with
more than one virus type [41,42], making ‘typing’ difficult.
Serological typing methods require access to standardised
reagents, including reference antisera, or reference strains for all
26 BTV serotypes, which can be difficult to produce and could
themselves represent a potential infection risk.
Sensitive and specific nucleic-acid based typing assays (by RT-
PCR and sequencing) that were previously reported for six
European serotypes, including BTV-1, -2, -4, -8, -9 and -16 [16],
give clear advantages in terms of speed, sensitivity and specificity
over established serological tests. Sequencing of the cDNA
amplicons generated in these assays and phylogenetic comparisons
to other strains that had previously been analysed also made it
possible to identify individual virus lineages in a manner that is not
currently possible by serological techniques.
The recent availability of full-length Seg-2 sequence data from
multiple isolates of individual types, including both eastern and
western strains, has facilitated the selection and evaluation of a
complete set of ‘serotype-specific’ primers for all 26 BTV
serotypes. The specificity of amplification was confirmed in each
case by a lack of cDNA products amplified from the RNA of
closely related heterologous serotypes within the same Seg-2
nucleotype. The resulting assays which are described here, provide
rapid and reliable BTV serotype and strain identification (in less
than 24 hrs), and were used to identify incursions of multiple BTV
types into Europe and the USA.
Materials and Methods
Virus isolates
A total of 240 strains from the 26 different BTV serotypes, were
used in this study, including reference strains and both new and
historical field isolates from different geographical locations
(Table 1, S1 and S2). These viruses were isolated using
embryonated chicken eggs (ECE) (UK Home Office licence
number PPL 70/6213) and tissue culture techniques (KC cells -
originally provided by colleagues at the USDA lab in Laramie or
BHK-21 clone 13 (European Collection of Animal cell Cultures
[ECACC – 84100501]), from diagnostic samples including the
blood/spleen/lymph nodes of sick or dead animals. These samples
were not collected for research purposes, but were taken from
naturally infected/dead animals in the field, by qualified
veterinarians, as part of normal diagnostic testing procedures in
the respective countries. Further details of the isolates are provided
on the Orbivirus Reference Collection (ORC) web site at [43].
Extraction of Viral dsRNA
Double stranded (ds) RNA was extracted either from BTV
infected cells, using TrizolH (Invitrogen, USA) [44], from tissue
culture supernatant, or diagnostic samples, (including blood,
spleen, lymph nodes or liver) using the QIAamp Viral RNA Mini
Kit from Qiagen (Hilden, Germany), according to manufacturer’s
instructions. Each isolate was processed at different times to help
minimize the risk of sample-to-sample contamination.
Selection of serotype-specific oligonucleotide primers
Comparisons of full-length Seg-2 sequences from different BTV
types [17,18,45] has facilitated the identification of unique regions
RT-PCR Assays for Typing of 26 BTV Serotype
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the design of primers as potential targets in serotype specific RT-
PCR assays. Wherever possible at least three primer-pairs were
designed for each serotype – If isolates were available from both
eastern and western topotypes, one pair was designed for
amplification of isolates from both origins (A); one pair each for
specific amplification of isolates of an eastern origin (E), and one
pair from a western origin (W) respectively. Primers are designated
as follows: ‘BTV’ representing the bluetongue virus, followed by
serotype, ‘2’ representing Seg-2; a number corresponding to the
nucleotide position of the primer in Seg-2 of BTV; and ‘F’ or ‘R’
representing the forward or reverse primer respectively. Each
primer-pair was evaluated using reference strains of the other
serotypes as well as multiple and diverse isolates (where available)
of the homologous serotype, and of the most closely related
heterologous serotypes (from the same Seg-2 nucleotype) [17,24].
The primer-sequences selected for each BTV type were
compared (in silico) to Seg-2 sequence data for multiple strains of
the other 25 types, as well as other orbiviruses closely related to
BTV (as listed on ORC web site at [46]) to ensure that they would
not cross-react.
Reverse transcription and amplification of Seg-2
Two RT-PCR protocols were evaluated for amplification of
BTV Seg-2. These included a single-tube method using a One-
Step RT-PCR kit (Qiagen, Courtaboeuf, France), as previously
described by Mertens et al. [16]. The second protocol used the
SuperScript
TM III one-step RT-PCR system (Invitrogen) with high
fidelity platinumH Taq, which is designed for sensitive, high-
fidelity end-point detection and analysis of RNA templates
extracted from blood or cell culture supernatant, as described by
Maan et al. [21]. All primer-pairs were used as described
previously [21], with annealing conditions 255uC for 30 seconds.
After these reactions 5 microlitres of each cDNA product was
analyzed by electrophoresis on a 1% agarose gel, stained with
ethidium bromide then visualised under UV light. The identifi-
cation of each BTV serotype was dependent on detection of an
amplified product of the predicted size (Table S1 and S2).
Sequencing of RT-PCR amplicons
Confirmation of BTV type (as indicated by RT-PCR amplifi-
cation of a cDNA of the expected size) was obtained by direct
sequencing of the amplified products using ‘Big dye cycle
sequencing kit’ on an ABI 3730 DNA sequence analyzer, and
the same primers for sequencing. Analyses and comparisons of the
resulting nt sequence data were carried out using BLAST [47],
MEGA 5 [48] and Lasergene software (DNASTAR Inc., Madison,
Wis.).
Evaluation of RT-PCR assays for specificity
The original strain of BTV-25 has not yet been grown in cell
culture [49]. The serotype-specificity of primers and RT-PCR
assays were therefore evaluated using reference strains of the other
25 BTV types. Most of the reference strains used at IAH were
isolated in South Africa and belong to a ‘western’ topotype (w),
Table 1. Field isolates of BTV typed using Seg-2 based
serotype-specific RTPCR assays.
BTV serotype Origin ID*
BTV-1 Greece GRE2001/01
BTV-1 Greece GRE2001/02
BTV-1 Algeria ALG2006/01
BTV-1 Morocco MOR2006/06
BTV-1 Oman OMN2009/01
BTV-1 USA USA2004/02
BTV-3 USA USA1999/06
BTV-4 Oman OMN2009/09
BTV-5 USA USA2003/05
BTV-6 USA USA2006/01
BTV-6 Netherlands NET2008/04
BTV-6 Netherlands NET2008/05
BTV-6 Netherlands NET2008/06
BTV-8 Netherlands NET2006/01
BTV-8 Netherlands NET2006/02
BTV-8 Netherlands NET2006/03
BTV-8 Netherlands NET2006/04
BTV-8 Netherlands NET2006/05
BTV-8 Netherlands NET2006/06
BTV-8 Belgium BEL2006/01
BTV-8 Oman OMN2009/03
BTV-8 UK UKG2007/05
BTV-9 Libya LIB2008/01
BTV-9 Libya LIB2008/03
BTV-9 Libya LIB2008/06
BTV-9 Libya LIB2008/07
BTV-9 Libya LIB2008/09
BTV-9 India IND2005/01
BTV-9 India IND2005/02
BTV-9 India IND2005/03
BTV-9 India IND2005/07
BTV-9 India IND2005/08
BTV-14 USA USA2003/03
BTV-15 Israel ISR2006/11
BTV-16 Oman OMN2009/02
BTV-19 USA USA2003/04
BTV-22 USA USA2002/02
BTV-24 USA USA2007/01,
BTV-24 Israel ISR2009/04
BTV-25 Switzerland SWI2008/01
BTV-26 Kuwait KUW2010/02
BTV-26 Kuwait KUW2010/03
BTV-4 and -24 Israel ISR2008/02
BTV-6 and -8 Germany GER2008/06
BTV-6 and -8 Germany GER2008/07
BTV-6 and -8 Netherlands NET2008/09
BTV-6 and -8 Netherlands NET2008/11
BTV-9 and -16 Turkey TUR2000/06
BTV-9 and -16 Turkey TUR2000/07
*Institute for Animal Health, Pirbright (IAH-P) dsRNA virus reference collection
number. More information concerning the origins of these isolates is available
at http://www.reoviridae.org/dsRNA_virus_proteins/ReoID/BTV-isolates.htm.
doi:10.1371/journal.pone.0032601.t001
Table 1. Cont.
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originated from Cyprus, Portugal, Pakistan, Switzerland and
Kuwait respectively. The reference strain of BTV-17w was derived
from the USA, while BTV-20e, 21e, 23e were isolated in Australia
[51,52,53]. The primer-pairs were also tested using dsRNA
preparations from the most closely related heterologous BTV
serotypes in each case (same nucleotype - Maan et al [17,21]), as
well as multiple isolates of other closely related Orbivirus species,
including currently available African horse sickness virus (AHSV –
reference strains of all 9 serotypes), Epizootic haemorrhagic
disease virus (EHDV - reference strains of all 7 serotypes), Equine
encephalosis virus (EEV - reference strains of all 7 serotypes), Pata
virus (PATAV - CAF1968/01), Andasibe virus (ANDV -
MAD1979/01), Tilligerry virus (TILV - AUS1978/03), Mitchell
River virus (MRV - AUS1971/01), Wallal Mudjinbarry virus
(MUDV - AUS1982/03). In each case the Institute for Animal
Health, Pirbright (IAH-P) ‘dsRNA virus reference collection
number’ is composed of country code, year, and the number of
the isolate in that year from that country. More details about these
orbiviruses can be found on ORC web site at [46].
Results
Testing of previously published RT-PCR assays [54,55] has
shown that primers developed using Seg-2 data from a single
isolate, may not work reliably (or may give poor amplification)
with other isolates of the same type (data not shown), reflecting
significant intra-type sequence variation within Seg-2. Therefore,
wherever possible full-length Seg-2 sequence data were compared
for multiple isolates of each serotype, to identify relatively more
conserved regions prior to the design of type specific primers
[18,21,45]. However, high levels of intra-type variation (e.g.
between topotypes) can make it difficult to detect all isolates of a
serotype using a single pair of Seg-2 primers. Under these
circumstances, multiple primer-pairs were designed that could be
used collectively to amplify all variants within the serotype.
Selection of serotype specific primers for different BTV
‘types’
We previously reported RT-PCR based typing assays for six
European BTV serotypes 1, 2, 4, 8, 9 and 16 [16]. Further
introductions of exotic serotypes into Australia, Europe and
America, have prompted the design of a complete set of Seg-2
amplification primers for typing all 26 BTV serotypes.
Sequence data generated for Seg-2 of multiple field, reference
and vaccine strains (where available - Table S1 and S2) were
compared to select ‘foot-print’ sequences for primers that could be
used to distinguish and detect each of the 26 BTV serotypes.
Details of oligonucleotide primer sequences, specific primer
positions, level of specificity and the product sizes expected with
different sets of serotype-specific primers for each of the 26 BTV
serotypes is given in Table S1 and S2. In some cases (e.g. BTV-7, -
21 -25 and -26) the number of available virus strains and/or
sequences is limited, which (as already discussed) may impose
limits on primer type-specificity, that will require future re-
evaluation and re-design.
Evaluation of RT-PCR assays for type specificity
Reaction conditions were optimized for each primer pair, as
described in the materials and methods section. Each of the 25
BTV reference strains (BTV-1 to 24 and BTV-26) listed in Table
S1 and S2, was tested to confirm the specificity of at least three
different primer sets for each of 26 BTV serotypes. In most cases
no amplified products were detected from heterologous serotypes,
even within the same nucleotype, providing an initial validation
for the use of these primers to discriminate between BTV types.
Each of the primer-pairs generated an abundant cDNA amplicon
of the expected size, from RNA of the homologous BTV reference
strain, although some also generated additional minor bands of an
‘incorrect’ size in these reactions (Table S1 and S2, Figure 1).
The Seg-2 primers for each BTV serotype were also evaluated
for type specificity, by in silico comparisons to Seg-2 sequence data
for multiple other BTV isolates and other related orbiviruses, as
listed on ORC web site at [46] (data not shown). These
comparisons indicated no high-similarity binding sites in heterol-
ogous BTV serotypes or virus-species that are likely to result in
mispriming under the reaction conditions used. The majority of
primers listed in Table S1 are therefore thought to be genuinely
serotype-specific (as indicated), although novel strains may appear
in the future that are more ‘cross-reactive’.
However, some primer-pairs, for the serotypes in nucleotype A
(BTV-4, -10, -11, -17, -20 and -24), nucleotype D (BTV-8, -18 and
-23), BTV-16 and BTV-26 (as listed in Table S2) were not entirely
type-specific. In these cases they also amplified Seg-2 sequences
from some of the most closely related heterologous serotypes,
generating amplicons of the expected size. However, unlike real-
time PCR assays, both the ‘conventional’ type-specific primers and
these ‘non-type-specific’ primers can be used to sequence the Seg-
2 cDNA amplicons that they generate, providing definitive
serotype and strain identification, via phylogenetic comparisons.
Use of RT-PCR assays for typing field isolates from recent
BTV outbreaks
The type-specific RT-PCR assays and sequencing methods
described here were used for primary identification or confirma-
tion of serotype, for multiple field strains of BTV. Confirmation of
the initial RT-PCR typing results, was obtained by direct
sequencing of the amplified products from Seg-2 using the same
RT-PCR primers, as sequencing primers. The resultant sequences
were subjected to either BLAST analysis or phylogenetic
comparisons to Seg-2 sequence data for multiple isolates of the
26 BTV serotypes (including a total of over 300 Seg-2 sequences,
including both eastern and western strains). The BTV serotype
was confirmed by detection of high levels of sequence identity to
reference strains of the relevant type.
The strains identified using these methods included BTV-1
isolates from the Mediterranean region (Table S1 and S2). Two
Greek strains were identified as BTV-1e, related to viruses from
India (Table 1) [45]. In contrast two incursions in Algeria and
Morocco were identified as BTV-1w, one of which spread to
south-west France during November 2007 (Table 1) [56].
Type specific RT-PCR assays were also used during August-
September 2006 for the primary identification of BTV-8 in clinical
samples from animals in the Maastricht region of northern
Europe. In August 2007, BTV-8 was again identified in the UK
(the first recorded BTV incursion in the UK). Late in 2008/early
2009, BTV-6 was identified in the Netherlands [21], BTV-11 in
Belgium [57], BTV-25 in Switzerland [19] and BTV-26 in Kuwait
(Table 1) [18].
The assays and primers described here were also used at IAH to
identify several BTV isolates sent from America (in 2006–2007), as
BTV-1, -3, -5, -6, -14, -19, -22 and -24 respectively [36], types that
were previously exotic to the USA. Isolates from India (BTV-9e),
Oman (BTV-1w, -4w, -8w and -16w) (Figure 2); Israel (BTV-15w
and BTV-24w - [33]) were also identified using these techniques
(Table 1). The amplification of BTV-9 from Libya (Table 1 and
Table S1) is shown in Figure S1. Data for the amplification and
RT-PCR Assays for Typing of 26 BTV Serotype
PLoS ONE | www.plosone.org 4 February 2012 | Volume 7 | Issue 2 | e32601Figure 1. Electrophoretic analysis of cDNA products from Seg-2 of BTV reference strains using ‘type-specific’ primer-pairs for
individual serotypes (Panels A–F). Panel A: PCR amplicons were generated from Seg-2 of BTV-1/RSArrrr/01 using primer-pairs ‘1A1’ 21621 bp,
‘1A2’ 2864 bp, and ‘1W1’ 21743 bp (lanes 1, 2, and 3 respectively). PCR amplicons were generated from Seg-2 of BTV-2/RSArrrr/02 using primer-pairs
‘2A1’ 21800 bp, ‘2A2’ 22343 bp and ‘2W2’ 21246 bp (lanes 4, 5 and 6 respectively). PCR amplicons were generated from Seg-2 of BTV-3/RSArrrr/03
using primer-pairs ‘3W1’ 2648 bp, ‘3W2’ 2480 bp and ‘3W3’ 2652 bp (lanes 7, 8 and 9 respectively). PCR amplicons were generated from Seg-2 of
BTV-4/RSArrrr/04 using primer-pairs ‘4W1’ 22045 bp, ‘4W4’ 21071 bp and ‘4W5’ 2929 bp (lanes 10, 11 and 12 respectively). Panel B: PCR amplicons
were generated using primer-pairs ‘5W1’ 21362 bp, ‘5W2’ 21280 bp and ‘5W3’ 22124 bp from Seg-2 of BTV-5/RSArrrr/05 (lanes 1, 2 and 3
respectively). PCR amplicons were generated from Seg-2 of BTV-6/RSArrrr/06 using primer-pairs ‘6W1’ 21724 bp, ‘6W3’ 21303 bp and ‘6W4’
22051 bp (lanes 4, 5 and 6 respectively). PCR amplicons were generated from Seg-2 of BTV-7/RSArrrr/07 using primer-pairs ‘7W1’ 21798 bp, ‘7W2’
21577 bp and ‘7W3’ 21609 bp (lanes 7, 8 and 9 respectively). PCR amplicons were generated from Seg-2 of BTV-8/RSArrrr/08 using primer-pairs
‘8W4’ 2363 bp, ‘8W5’ 22216 bp and ‘8W6’ 2562 bp (lanes 10, 11 and 12 respectively). Panel C: PCR amplicons were generated using primer-pairs
‘9W1’ 21093 bp, ‘9W2’ 2961 bp from Seg-2 of BTV-9/RSArrrr/09 (lanes 1 and 2 respectively), and from Seg-2 of BTV-9/BUL1999/01 using primer-pair
‘9E1’ 21105 bp (lane 3). PCR amplicons were generated from Seg-2 of BTV-10/RSArrrr/10 using primer-pairs ‘10W4’ 2964 bp, ‘10W5’ 21094 bp and
‘10W6’ 21109 bp (lanes 4, 5 and 6 respectively). PCR amplicons were generated from Seg-2 of BTV-11/RSArrrr/11 using primer-pairs ‘11W4’
21077 bp, ‘11W5’ 21096 bp and ‘11W6’ 2355 bp (lanes 7, 8 and 9 respectively). PCR amplicons were generated from Seg-2 of BTV-12/RSArrrr/12
using primer-pairs ‘12W1’ 21613 bp, ‘12W2’ 2892 bp and ‘12W3’ 21326 bp (lanes 10, 11 and 12 respectively). Panel D: PCR amplicons were
generated from Seg-2 of BTV-13/RSArrrr/13 using primer-pairs ‘13W2’ 21323 bp, ‘13W3’ 21236 bp and ‘13W4’ 21655 bp (lanes 1, 2 and 3
respectively). PCR amplicons were generated from Seg-2 of BTV-14/RSArrrr/14 using primer-pairs ‘14W1’ 2850 bp, ‘14W2’ 21581 bp and ‘14W3’
2849 bp (lanes 4, 5 and 6 respectively). PCR amplicons were generated from Seg-2 of BTV-15/RSArrrr/15 using primer-pairs ‘15W1’ 21823 bp, ‘15W2’
2991 bp and ‘15W3’ 21067 bp (lanes 7, 8 and 9 respectively). PCR amplicons were generated from Seg-2 of BTV-16/RSArrrr/16 using primer-pairs
‘16A3’ 2851 bp, ‘16E2’ 21288 bp (lanes 10 and 11 respectively) and from Seg-2 of BTV-16/NIG1982/10 using primer-pair ‘16W2’ 2726 bp (lane 12).
Panel E: PCR amplicons were generated from Seg-2 of BTV-17/RSArrrr/17 using primer-pairs ‘17W1’ 21256 bp, ‘17W4’ 2689 bp and ‘17W3’
21090 bp (lanes 1, 2 and 3 respectively). PCR amplicons were generated from Seg-2 of BTV-18/RSArrrr/18 using primer-pairs ‘18W1’ 21021 bp,
‘18W4’ 21556 bp and ‘18W3’ 21381 bp (lanes 4, 5 and 6 respectively). PCR amplicons were generated from Seg-2 of BTV-19/RSArrrr/19 using primer-
pairs ‘19W1’ 21787 bp, ‘19W2’ 21680 bp and ‘19W3’ 21494 bp (lanes 7, 8 and 9 respectively). PCR amplicons were generated from Seg-2 of BTV-20/
RSArrrr/20 using primer-pairs ‘20E1’ 21324 bp, ‘20E2’ 21257 bp and ‘20E3’ 2827 bp (lanes 10, 11 and 12 respectively).Panel F: PCR amplicons were
generated from Seg-2 of BTV-21/RSArrrr/21 using primer-pairs, and ‘21E3’ 21524 bp, ‘21E2’ 21726 bp and ‘21E1’ 21320 bp (lanes 1, 2 and 3
respectively). PCR amplicons were generated from Seg-2 of BTV-22/RSArrrr/22 using primer-pairs ‘22W1’ 21074 bp, ‘22W2’ 22034 bp and ‘22W3’
22211 bp (lanes 4, 5 and 6 respectively). PCR amplicons were generated from Seg-2 of BTV-23/RSArrrr/23 using primer-pairs ’23E1’ 21548 bp, ‘23E2’
21623 bp and ‘23E3’ 21421 bp (lanes 7, 8 and 9 respectively). PCR amplicons were generated from Seg-2 of BTV-24/RSArrrr/24 using primer-pairs
‘24W1’ 21776 bp, ‘24W2’ 21557 bp and ‘24W3’ 22021 bp (lanes 10, 11 and 12 respectively).Lane M: 1 Kb marker. +C is a positive control using RNA
from BTV-6/RSArrrr/06, with primer-pair BTV-6/2/301F & BTV-6/2/790R 21631 bp – [21]. 2C is a negative water control. For primer position and
sequence see Table S1 and S2. The use of type specific primers for BTV-26 was recently published by [18,22].
doi:10.1371/journal.pone.0032601.g001
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are not shown in this paper.
Unlike previous serological methods, the type specific RT-PCR
assays can and have provided direct positive identification of
individual serotypes, as part of mixed serotype infections/isolates,
including BTV-4w and -24w from Israel; BTV-6w and -8w from
Germany and the Netherlands; BTV-9 and -16 from Turkey.
Discussion
We describe a complete set of primer-pairs, together with an
initial evaluation of their use in RT-PCR amplification assays to
identify the 26 serotypes of BTV. The virus strains used in this
study originated from all over the world, including reference
strains, new and historic isolates from Europe, America, the
Middle East, Africa, Australia and the Indian subcontinent,
helping to demonstrate the relevance of these assays for detection
and typing of different BTV topotypes.
Genome segment 2 was chosen as the target for development of
serotype specific RT-PCR based assays, because it encodes the
main type-specific antigen and outer-capsid protein VP2 of BTV
[17,58,59,60]. However, primers previously designed for Seg-2 of
American [55] and Australian [54] isolates, in most cases
amplified only small or partial products from the RNA of
homologous BTV reference strains (same serotype). This reflects
the high level of nt sequence variation (up to 32%) that can exist in
Seg-2 between different isolates of the same serotype from different
geographic regions (different topotypes) [24,45].
Primers were recently also described for identification of
contaminating serotypes in vaccine studies [61]. However, the
specificity of amplification and detection was not widely validated
with different topotypes, or isolates of the 26 BTV serotypes,
leaving some uncertainty concerning their wider specificity.
The specificity, reproducibility and reliability of the RT-PCR
assays described here were tested using reference strains of BTV-1
to BTV-26, field strains of the homologous type (representing
Figure 2. Neighbour-joining tree, showing relationships in Seg-2 between reference and field strains of BTV-1w, 4w, 8w and 16w
from Oman. The tree was constructed using distance matrices, generated using the p-distance determination algorithm in MEGA5 (500 bootstrap
replicates) [48]. BTV split into 26 distinct groups based on Seg-2 sequences, reflecting serological relationships between virus strains [18]. Reference
strains of BTV are shown in black and field isolates from Oman are shown in blue font. Isolate designations: IAH ‘dsRNA virus reference collection
number’ composed of country code, year, and the number of the isolate in that year from that country [66]. Full length Seg-2 sequences of BTV-1/
OMN2009/01, BTV-4/OMN2009/09, BTV-8/OMN2009/03 and 16/OMN2009/02 showed 95%, 94%, 93% and 73.6% nucleotide (nt) identity to the
reference strains of respective serotype, confirming their types and topotypic groups.Scale represents number of substitutions per site. Values at
major branching points represent NJ bootstraps.
doi:10.1371/journal.pone.0032601.g002
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belonging to different Orbivirus species (negative controls), as listed
on the ORC web site at [46]. For simplicity and ease of use, each
of the conventional RT-PCR assays uses the same amplification
conditions to generate cDNA amplicons from Seg-2 of distinct
virus-lineages and topotypes within each BTV serotype. All of the
primer-pairs generated a major cDNA amplicon of the expected
size, from RNA of the homologous BTV reference strain.
However, in some cases additional cDNA bands were also
generated that are not of the size predicted for the amplified
BTV Seg-2 sequences (e.g. primer set ‘17W3’ for BTV-17 –
Figure 1 (panel E) lane 3; Table S1 and S2). The synthesis of these
bands could be reduced by further optimisation for individual
primer pairs. However, the initial indication of virus type can also
be confirmed by sequence analysis of the cDNA amplicons (using
the same primers) and phylogenetic comparisons to previously
characterised strains of BTV-1 to BTV-26.
The RT-PCR assays can be applied directly to RNA extracted from
diagnostic samples of viraemic blood or tissues, and do not therefore
d e p e n do nv i r u si s o l a t i o n ,a d a p t a t i o nt og r o w t hi nc e l lc u l t u r e ,o r
neutralisation assays, which can collectively take several weeks to give a
reliable identification of virus- type. It can also be difficult to identify
different BTV types within a single ‘mixed’ isolate, or identify the
specificity of neutralising antibodies from animals infected or
vaccinated with more than one serotype, using serological methods.
Conventional and real-time RT-PCR assays have been used
routinely since 2006, for the identification of different BTV
serotypes in diagnostic samples of tissue, blood, or cell-culture
materials, within the BTV reference laboratory at IAH Pirbright
[21,45,62,63]. Samples with CT values of ,30 by real-time RT-
PCR (equivalent to 200 to 1000 copies per ml of blood) also
reliably generate cDNA amplicons by these conventional RT-PCR
assays targeting Seg-2. Data concerning real-time RT-PCR
sensitivity for detection of different topotypes of the BTV serotypes
found in Europe [BTV-1, 2, 4, 6, 8, 9, 11 and 16], was supplied by
Laboratoire Service International (LSI).
It is difficult to give a direct comparison of either conventional
or real-time RT-PCR assays, in terms of sensitivity, to virus
isolation or titration in cell culture. The relative infectivity of
different BTV strains depends on their level of adaptation to the
cell-culture system used. Indeed, many wild type BTV strains
(from diagnostic samples) will not grow directly in mammalian cell
cultures (e.g. BHK-21 cells). However, in our hands BTV isolation
in KC cells (derived from Culicoides sonorensis) is usually successful
for samples with CT values ,30 to 32. The sensitivity of the
conventional RT-PCR assays described here is therefore directly
comparable to that of virus isolation in KC cells, although it is less
affected by sample degradation and bacterial contamination.
Eastern and western strains of the same serotype were available
for BTV-1, 2, 9 and 16. ‘Type’ specific ‘A’ (all) primers were
identified that would amplify Seg-2 from both eastern and western
strains of BTV-1 and 2. However, the different topotypes of BTV-
9 and BTV-16 are too divergent for ‘common’ type-specific
primers and additional primer pairs were therefore designed to
allow amplification of the more diverse strains (E and W) within
these types (Table S1 and S2).
RT-PCR assays were tested using RNA derived from infected cell
culture material, as well as clinical samples including blood, spleen,
lymph nodes and liver. In each case they were reliable and effective
for BTV typing. Although these RT-PCR assays are highly sensitive,
they detect different virus-specific molecules from those detected by
ELISA or competition ELISA (proteins/antigens or antibodies
respectively) and they will therefore have different diagnostic
applications.
The RT-PCR assays and sequencing primers targeting Seg-2
have already been used to identify multiple isolates from around
the world (Table S1 and S2) confirming their sensitivity,
specificity, speed and reliability for BTV typing. It has previously
been established using serological methods that multiple serotypes
of BTV are often present and can co-circulate in the same
endemic regions (as seen recently in Europe) [41,42]. The RT-
PCR assays described here have been used to identify several
isolates containing mixed BTV types, which would previously have
remained untyped by VNT. These observations suggest that co-
infection by different types may be a more common features of
BTV epidemiology than previously recognised.
The sequences of primers for the amplification and sequencing
of Seg-2 from different BTV serotypes are available via the
internet at [64]. Some of the primer sets were designed based on
only a limited number of isolates (e.g. BTV-7, -18, -21, -25 and -
26) and consequently do not include different topotypes. If new
isolates of these types are identified that are not detected by the
primers listed here (which is considered likely), further sequencing
of Seg-2 will support the design and updating of typing primers.
There remains a need to generate sequence data for Seg-2 of BTV
vaccine strains, to allow the design of RT-PCR primers to distinguish
them as distinct lineages of field strains, as already done for several
Europeanserotypes [16].Thiswouldhelp to identify field transmission
of ‘live’ vaccines, as reported for BTV-6 and -11 in northern Europe
and BTV-2 in the Mediterranean region [21,57,65].
Phylogenetic comparisons of BTV Seg-2 sequences generated
using the conventional primers described here will help to
determine the worldwide prevalence, distribution and variability
of different BTV types and topotypes, improving our understand-
ing of their epidemiology and transmission. The data generated
will also help to inform the design and implementation of future
control strategies, including vaccination and the development of
novel vaccines.
Supporting Information
Figure S1 Electrophoretic analysis of cDNA products
from Seg-2 of BTV-9 isolates from Libya 2008 using
‘type-specific’ primer-pairs. PCR amplicons were generated
from Seg-2 of LIB2008/01, LIB2008/09, LIB2008/03, LIB2008/
07 and LIB2008/06 using primer-pair ‘9W1’ 21093 bp (lanes 4,
6–9 respectively). RNA of BTV-5/RSArrrr/05 was used as a
heterologous control (lane 5). Lanes 1 and 2 are positive controls
using RNA from BTV-9/RSArrrr/09 and BTV-9RSAvvv1/09
respectively. Lane 3 has non-template negative control.
(TIF)
Table S1 Primer-pairs for type-specific amplification and
sequencing of Seg-2 from BTV-1 to BTV-26 in RT-PCR assays.
(XLS)
Table S2 Additional primer-pairs for amplification and se-
quencing of Seg-2 from BTV-1 to BTV-26 in RT-PCR assays.
(XLS)
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